Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. (Q36945656)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1 reference

Erik H van der Heijden

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Wim Oyen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Lioe-Fee de Geus-Oei

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Frans H M Corstens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1654-1664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17879371%20AND%20SRC:MED&resulttype=core&format=json

Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Prognostic value of stage grouping and TNM descriptors in lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

The mechanism of accumulation of tumour-localising radiopharmaceuticals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Evaluation of the solitary pulmonary nodule by positron emission tomography imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

FDG-PET in staging lung cancer: how does it change the algorithm?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron-emission tomography and assessment of cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Value of FDG-PET in the management of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Update of the FDG PET search strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Clinical trial designs for predictive marker validation in cancer treatment trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Update in PET imaging of nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Use of PET to monitor the response of lung cancer to radiation treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Does the FDG Uptake of Primary Non-Small Cell Lung Cancer Predict Prognosis? A Work in Progress

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

[(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

FDG-PET imaging in the management of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron emission tomography in the management of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Surgery for second lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Second surgical intervention for recurrent and second primary bronchogenic carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021

Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22979

7 January 2021